## **Core Concept**
The process of obtaining ethical clearance is crucial in the clinical trials of drugs to ensure that the rights and welfare of participants are protected. Clinical trials are typically divided into four phases: Phase I (first-in-human trials), Phase II (proof-of-concept and dose-finding), Phase III (confirmatory trials), and Phase IV (post-marketing surveillance). Each phase has distinct objectives and requirements.

## **Why the Correct Answer is Right**
The correct answer, **Phase IV**, is the post-marketing surveillance phase. During this phase, the drug is already approved and on the market. The primary goal of Phase IV trials is to monitor the drug's performance in a larger, more diverse population and to identify any long-term or rare side effects. Since the drug has already undergone rigorous testing and has been approved by regulatory authorities, the need for extensive ethical clearance is less stringent compared to earlier phases. However, it's essential to note that some form of monitoring and ethical oversight still exists.

## **Why Each Wrong Option is Incorrect**
- **Option A (Phase I):** This is the first phase of testing in human subjects and primarily assesses the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics. Given the first-in-human nature, rigorous ethical clearance is necessary.
- **Option B (Phase II):** This phase aims to obtain preliminary data on whether the drug works in people who have a certain disease or condition. Extensive ethical clearance is required to ensure participants' safety and rights.
- **Option C (Phase III):** Conducted on large patient groups, this phase confirms efficacy, monitors side effects, compares the drug to commonly used treatments, and collects information that will allow the experimental drug to be used safely. Ethical clearance is critical here due to the large number of participants and the comparative nature of the trials.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that while ethical clearance might be less stringent or differently focused in Phase IV, it's not entirely exempt. Researchers must still adhere to guidelines that protect patient rights and ensure the integrity of the data collected.

## **Correct Answer:** D. Phase IV.